Select your country
Select a country to go to the website of the respective STADA sales company.
Czech Republic (1)
United Kingdom (4)
STADA: Domination and profit and loss transfer agreement between STADA Arzneimittel AG and Nidda Healthcare GmbH takes effect / beginning of acceptance period for severance offer
- Investor News
Bad Vilbel, March 20, 2018 – The domination and profit and loss transfer agreement (DPLA) between Nidda Healthcare GmbH (Nidda Healthcare) as the controlling entity and STADA Arzneimittel AG (STADA) as the dependent company was entered into the commercial register of the Company at the District Court of Frankfurt am Main on March 20, 2018. The inter-company agreement that was approved by STADA’s Extraordinary General Meeting on February 2, 2018 thus takes effect.
STADA shareholders now have the opportunity to tender their shares to Nidda Healthcare in return for a compensation in the amount of €74.40 per share through their custodian bank. The acceptance period for this offer expires two months after the day on which the entry of the DPLA in the commercial register pursuant to Section 10 of the German Commercial Code (HGB) was announced. Should a duly submitted petition for a court ruling on the severance or the compensation be made to the court determined in Section 2 of the German Act on Appraisal Proceedings (Spruchverfahrensgesetz), the period shall end two months after the day on which the last petition that is decided upon is announced in the Federal Gazette (Bundesanzeiger).
Those remaining STADA shareholders who do not accept the severance offer remain shareholders of the Company and receive for the duration of the contract – instead of an annual dividend – a recurring compensation payment payable for each full fiscal year of STADA for each STADA share in the amount of €3.82 gross or €3.53 net at current tax rates.
Additional information for journalists
STADA Arzneimittel AG / Media Relations / Stadastraße 2–18 / 61118 Bad Vilbel – Germany / Phone: +49 (0) 6101 603-165 / Fax: +49 (0) 6101 603-215